- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: Quantitative assessment of mAb Fc glycosylation of CQA importance by capillary electrophoresis. (Pubmed Central) - Oct 4, 2019 Therefore, if effector function is the main mode of action of a monoclonal antibody therapeutic, microheterogeneity of this Fc glycosylation such as core fucosylation (for antibody-dependent cell-mediated cytotoxicity, ADCC), galactosylation (for complement-dependent cytotoxicity, CDC) and sialylation (for anti-inflammatoryfunction) 5 should be closely monitored in each phase of product development 6. On the other hand, albeit not important for the above listed functions, the presence of high mannose type glycans should be scrutinized as it greatly affects serum half-life via interaction with mannose-binding lectins (MBL) in the liver 7.
- |||||||||| Entyvio (vedolizumab) / Takeda, Humira (adalimumab) / Eisai, AbbVie
Journal: Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis. (Pubmed Central) - Oct 4, 2019 P3 In this trial involving patients with moderately to severely active ulcerative colitis, vedolizumab was superior to adalimumab with respect to achievement of clinical remission and endoscopic improvement, but not corticosteroid-free clinical remission. (Funded by Takeda; VARSITY ClinicalTrials.gov number, NCT02497469; EudraCT number, 2015-000939-33.).
- |||||||||| Humira (adalimumab) / AbbVie
Trial completion date, Trial primary completion date, HEOR: Rheumatoid Arthritis Satisfaction Outcome Research (clinicaltrials.gov) - Oct 3, 2019 P=N/A, N=840, Recruiting, Trial completion date: Mar 2020 --> Sep 2020 | Trial primary completion date: Mar 2020 --> Sep 2020 Trial completion date: Sep 2019 --> Dec 2019 | Trial primary completion date: Sep 2019 --> Dec 2019
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, tacrolimus / Generic Mfg., Humira (adalimumab) / Eisai, AbbVie
Review, Journal: Macular edema associated with non-infectious uveitis: pathophysiology, etiology, prevalence, impact and management challenges. (Pubmed Central) - Oct 3, 2019 However, immunomodulators such as methotrexate, tacrolimus, azathioprine, cyclosporine and mycophenolate mofetil together with anti-tumor necrosis factor-α (anti-TNF alpha) monoclonal antibodies such as adalimumab and infliximab, may be required to control the inflammation and the associated ME in refractory cases, or when an underlying disease is present. This review of the literature will focus mostly on the non-infectious UME.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: Treatment Patterns and Sequencing in Patients With Inflammatory Bowel Disease. (Pubmed Central) - Oct 2, 2019 Physicians should direct patients to the reliable resources of information and educate them in online resource assessment, thereby improving treatment outcomes. While current treatment options seem effective in a proportion of patients with UC and CD, others require multiple lines of therapy, suggesting an unmet need for alternative treatments in UC and CD to achieve disease control.
- |||||||||| Clinical, Review, Journal, Monotherapy: Efficacy of Monotherapy with Biologics and JAK Inhibitors for the Treatment of Rheumatoid Arthritis: A Systematic Review. (Pubmed Central) - Oct 2, 2019
Despite recommendations suggesting that biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) should be used in combination with methotrexate in the treatment of rheumatoid arthritis (RA), up to one-third of patients with RA are treated with monotherapy...Forty-four monotherapy studies of abatacept, adalimumab, baricitinib, certolizumab pegol, etanercept, sarilumab, sirukumab, tocilizumab, and tofacitinib reported in 71 publications were identified...There is, however, a need for longer-term head-to-head trials to establish positioning of these interventions in the treatment algorithm for RA. Pfizer.Plain Language Summary: Plain language summary available on the journal website.
- |||||||||| Xeljanz (tofacitinib) / Pfizer, Humira (adalimumab) / Eisai, AbbVie
Journal: JAK Inhibitors in Rheumatology (Pubmed Central) - Sep 30, 2019 In the placebo-controlled trials, venous thromboembolic events (VTE) were more common in the baricitinib treated patients. The VTE rate does not appear to be elevated in baricitinib treated patients compared to RA cohorts however.In conclusion, JAK inhibitors are a powerful new treatment of RA and likely many other rheumatic diseases and fulfill an unmet need since they may be taken orally.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Stelara (ustekinumab) / J&J, Humira (adalimumab) / Eisai, AbbVie
Clinical, Journal: A series of seton techniques involving "top-down therapy" for patients with Crohn's disease who initially presented with perianal fistulas. (Pubmed Central) - Sep 29, 2019 The VTE rate does not appear to be elevated in baricitinib treated patients compared to RA cohorts however.In conclusion, JAK inhibitors are a powerful new treatment of RA and likely many other rheumatic diseases and fulfill an unmet need since they may be taken orally. Our seton drainage techniques via the "top-down" approach represent a promising avenue for treating perianal fistulas in patients with CD.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie
Biomarker, Preclinical, Journal: Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel Disease. (Pubmed Central) - Sep 28, 2019 In an ex vivo human IBD tissue culture model, V565 inhibition of tissue phosphoprotein levels and production of inflammatory cytokine biomarkers was similar to infliximab, demonstrating efficacy when present at the disease site. Taken together, results of these studies provide confidence that oral V565 dosing will be therapeutic in IBD patients where the mucosal epithelial barrier is compromised.
- |||||||||| RECYCLING INFLIXIMAB: AN "ECOLOGICAL" THINKING AFTER SURGERY IN CROHN´S DISEASE (Poster Exhibition - Hall 7) - Sep 28, 2019 - Abstract #UEGW2019UEGW_4198;
2009 azathioprine was started and suspended 4 months later (myelosuppression), clinical remission was maintained with5ASA...2013 due to moderate endoscopic activity(EA) and biopsies compatible with CD, patient starts parenteral methotrexate(MTX) achieving clinical remission...In Jan2015 IFX is suspended after 7months of therapy, switching to Adalimumab(ADA)...Authorization request to Ustekinumab(UST)was done due to reluctance of patient to any surgical intervention...Request for Vedolizumab(VEDO)was done and patient started this treatment on Jan2016...IFX dose reduction to 5mg/kg every 4 weeks was performed in Apr2018. In Aug2018 (last visit) patient is asymptomatic with HBI2, CRP5,35mg/L and FC12mcg/g.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
HEPATOSPLENIC T-CELL LYMPHOMA IN BIOLOGIC THERAPY - WHEN THE CURE CAN BE WORSE THAN THE DISEASE (Poster Exhibition - Hall 7) - Sep 28, 2019 - Abstract #UEGW2019UEGW_4158; In the latter group risk increases when duration of combination therapy exceeds 2 years. We propose that combined usage of thiopurine and biologic therapy in this cohort of patients for more than two years should be minimised, and in more difficult to treat cases, it may be better to consider an alternative biologic agent.
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
Journal: A 67-Year-Old Man With Psoriatic Arthritis and New-Onset Dyspnea. (Pubmed Central) - Sep 28, 2019 Joint involvement had previously been controlled with methotrexate, which was discontinued 15 years ago after resolution of his symptoms. He developed a polyarthritis flare a year ago, and adalimumab was initiated with good response.
- |||||||||| Remicade (infliximab) / Mitsubishi Tanabe, J&J, Humira (adalimumab) / Eisai, AbbVie, Rituxan (rituximab) / Roche, Biogen
Use of Rituximab on the treatment of Vogt–Koyanagi–Harada: a case report. () - Sep 26, 2019 - Abstract #EURETINA2019EURETINA_1169; Our patient presented with bilateral uveitis, choroidal folds and neurological and auditory manifestations, without dermatological symptoms.Early diagnosis and subsequent aggressive treatment may result in visual recovery. Initial treatment includes systemic corticosteroids, for a minimum of 6 months and immunosuppressive pharmacological therapy to reduce the frequency and severity of recurrences.Some investigators have suggested immunosuppression with agents such antimetabolites (Azathioprine, Methotrexate, MMF), calcineurin inhibitors (CsA) and biological agents (Infliximab and Adalimumab) as first-line.There are just a few case reports of the use of Rituximab in patients with VKH.
|